Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial

Journal of Ovarian Research

Nicola Colacurci¹  Daniela Mele¹  Raffaele Ianniello¹  Maria Rosaria Campitiello¹  Carlo Trotta¹  Maria Diletta D’Eufemia¹  Francesca Caprio¹ 

[1] Outpatient Fertility Clinic, Second University of Naples, Largo Madonna delle Grazie 1, Naples 80138, Italy

关键词: Ovarian sensitivity index;    IVF;    Poor-responder;    Myo-inositol;   

Others  :  1213913
DOI  :  10.1186/s13048-015-0167-x

 received in 2015-02-13, accepted in 2015-06-05,  发布年份 2015

【 摘 要 】

Background

The overall incidence of poor ovarian response in IVF cycles has been reported to be between 9 and 24 %. The management of these patients remains a significant challenge in assisted reproduction. The aim of the present study was to evaluate the effect of myo-inositol (MI) on ovarian function in poor responders undergoing ICSI.

Methods

The study is a prospective controlled observational trial, that involved 72 poor responders included in an ICSI program and divided into two groups; group A: 38 patients who have been assuming MI (4 g) + folic acid (FA) (400 μg) for the previous 3 months before the enrollment day; group B: 38 patients assuming FA (400 μg) alone for the same period. COH was carried out in the same manner in the two groups. The main goal was the assessment of oocytes retrieved number and quality; secondary endpoints were the Ovarian Sensitivity Index (OSI: n° oocytes retrieved/total Gonadotropins units × 1000), oestradiol levels on the day of hGC, fertilization rate, implantation rate, ongoing pregnancy rate.

Results

There was no significant difference between the two groups regarding oestradiol level, but total rec-FSH units were significantly lower (p = 0.004) and M2 oocytes rate significantly higer (p = 0.01) in group A. The ovarian sensitivity index was higher, reaching a statistical significance (p < 0.05), in the group of patients pre-treated with MI, showing an improvement in ovarian sensibility to gonadotropin.

Conclusions

Our results suggest that MI therapy in poor responders results in an increased of the number of oocytes recovered in MII and of the gonadotropin Ovarian Sensitivity Index (OSI), suggesting a MI role in improving ovarian response to gonadotropins. Therefore MI seems to be helpful in “poor responders” undergoing IVF cycles.

【 授权许可】

   
2015 Caprio et al.

【 参考文献 】

• [1]Wide L. Follicle-stimulating hormones in anterior pituitary gland from children and adults differ in relation to sex and age. J Endocrinol. 1989; 123:519-29.
• [2]Kailasam C, Keay SD, Wilson P, Ford WCL, Jenkins JM. Defining poor ovarian response during IVF cycles, in women aged <40 years, and its relationship with treatment outcome. Hum Reprod. 2004; 19(7):1544-7.
• [3]Fasouliotis SJ, Simon A, Laufer N. Evaluation and treatment of low responders in assisted reproductive technology: a challenge to meet. J Assist Reprod Genet. 2000; 17:357-73.
• [4]Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for ‘poor responders’ to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev. 2010; 1: Article ID CD004379
• [5]Kucuk T, Kozinoglu H, Kaba A. Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial. J Assist Reprod Genet. 2008; 25:123-7.
• [6]Kyrou D, Kolibianakis EM, Venetis CA, Papanilolaou EG, Bontis J, Tarlatzis BC. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systrmatic review and meta-analysis. Fertil Steril. 2009; 91:749-66.
• [7]Alviggi C, Humaidan P, Howles CM, Tredway D, Hillier SG. Biological versus chronological ovarian age: implications for assisted reproductive technology. Reprod Biol Endocrinol. 2009; 7:101. BioMed Central Full Text
• [8]Colacurci N, Caprio F, La Verde E, Trotta C, Ianniello R, Mele D et al.. Sequential protocol with urinary-FSH/recombinant-FSH versus standard protocol with recombinant-FSH in women of advanced age undergoing IVF. Gynecol Endocrinol. 2014; 30(10):730-3.
• [9]Kutateladze TG. Translation of the phosphoinositide code by PI effectors. Nat Chem Biol. 2011; 6(7):507-13.
• [10]Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012; 28(7):509-15.
• [11]Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013; 95(10):1811-27.
• [12]Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D chiro inositol in the polycystic ovary syndrome. N Engl J Med. 1999; 340(17):1314-20.
• [13]Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improce oocyte quality in intracitoplasmic sperm injectioncycles. A prospective, controlled randomized trial. Fertil Steril. 2009; 91(5):1750-4.
• [14]Jiang WD, Wu P, Kuang SY, Liu Y, Jiang J, Hu K et al.. Myo-inositol prevents copper-induced oxidative damage and changes in antioxidant capacity in various organs and the enterocytes of juvenile Jian carp (Cyprinus carpio var. Jian). Aquat Toxicol. 2011; 5(3-4):543-51.
• [15]Ciotta L, Stracquadanio M, Pagano I, Carbonaro A, Palumbo M, Gulino F. Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci. 2011; 15(5):509-14.
• [16]Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011; 26:1616-24.
• [17]Unfer V, Raffone E, Rizzo P, Buffo S. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrinol. 2011; 27(11):857-61.
• [18]Devroey P, Tjandraprawira K, Mannaerts B, Coelingh Bennink H, Smitz J, Bonduelle M et al.. A randomized, assessor-blind, group- omparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization. Hum Reprod. 1995; 10:332-7.
• [19]Devroey P, van Steirteghem A. A review of ten years experience of ICSI. Hum Reprod Update. 2004; 10:19-28.
• [20]Chiu TT, Tam PP. A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum. JAssist Reprod Genet. 1992; 9:524-30.
• [21]Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002; 17(6):1591-6.
• [22]Chiu TT, Rogers MS, Briton-Jones C, Haines C. Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod. 2003; 18(2):408-16.
• [23]Goud PT, Goud AP, Oostveldt PV, Dhont M. Presence and dynamic redistribution of type I inositol, 1,4,5-triphosphate receptor in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage division. Mol Hum Reprod. 1999; 5:441-51.